the AUC bile /AUC plasma ratio of linezolid after standard dosages was 1.35.
We recognize that the absence of real biliary pharmacokinetic/ pharmacodynamic data may be a limitation. However, these data confirm the potentially valuable role of linezolid in the treatment of cholangitis due to multidrug-resistant Enterococcus in LTx patients, since they meet the recommendations of good biliary penetration that are given in the Tokyo guidelines.
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Funding
This study was carried out as part of our routine work. 1,2 However, therapeutic failure with emergence of resistance has also been observed, especially associated with deep-seated infections (e.g. endocarditis, osteomyelitis), high inocula of bacteria and low-dose regimens.
Transparency declarations
3 Although 6 mg/kg has usually been the standard recommended dose regimen, in recent Infectious Diseases Society of America (IDSA) guidelines 8 -10 mg/kg regimens are considered for complicated bacteraemias and infective endocarditis (B-III). 4 We aimed to ascertain the clinical impact of susceptibility loss during daptomycin therapy in a cohort of patients with MRSA bacteraemia diagnosed and treated at 21 Spanish hospitals from June 2008 to December 2009. An infectious disease specialist prospectively followed the adult patients (.16 years old) with MRSA bacteraemia previously detected at the microbiology laboratory. 5 A standardized protocol with demographic and clinical information, including age, sex, morbidities, source and acquisition, diagnostic explorations, antibiotic treatment, follow-up and outcome, was applied. Extraction of blood cultures every 72 h until they were sterile was recommended in the protocol (though not mandatory for inclusion in the study). Episodes of documented bacteraemia for ≥7 days were classified as persistent bacteraemia. Daptomycin was the definitive therapy when it was administered immediately after obtaining antibiotic susceptibility information, either alone or combined with other antibiotic agents for at least 7 days, or otherwise until sterile blood cultures were obtained or the patient's death. For outcome, therapeutic failure included patients in which MRSA was still yielded by blood cultures despite daptomycin therapy (microbiological failure) as well as those receiving daptomycin as definitive therapy who died within 30 days of bacteraemia onset. Isolates were sent to a central reference laboratory. Susceptibility testing and molecular identification of all MRSA isolates were performed as published previously. 5 Associations between different variables and final outcomes (microbiological and clinical failure) were assessed using two-tailed Fisher's exact test. Differences were considered to be statistically significant when P values were ≤0.05. SPSS v15 was used for all the analyses. The study was approved by the Spanish Network for Research in Infectious Diseases (REIPI) as well as the Institutional Review Board of each participating centre. Because no direct patient contact was planned, the requirement for informed consent was waived.
Among 579 episodes of MRSA bacteraemia included in our study, daptomycin was used as initial therapy in 44/518 (8%) patients, while 124/518 (24%) patients received the antibiotic as definitive therapy: 77 (65%) at 6 mg/kg and 41 (35%) at higher doses (NB -in 6 patients we did not know the exact doses of daptomycin used). Concomitantly with daptomycin, 13 (10%) patients received other antibiotics with anti-staphylococcal activity: rifampicin (n¼ 6), aminoglycosides (n¼ 3), vancomycin, linezolid, teicoplanin and rifampicin plus gentamicin (n¼ 1, each). Persistent bacteraemia was diagnosed in 22 of 124 (18%) episodes treated with daptomycin. Their main characteristics are summarized in Table 1 Few clinical reports of daptomycin therapeutic failures with emergence of resistance have been published until now; most of the patients were treated with low doses of daptomycin or had deep infections associated with high inocula of bacteria. 6 Two of these studies demonstrated daptomycin susceptibility loss. First, in a clinical trial that compared daptomycin (6 mg/kg) with standard therapy against S. aureus bacteraemia, isolates with reduced susceptibility to daptomycin emerged in 6 of the 19 episodes (32%) with persistent or relapsing bacteraemia. 7 Secondly, in a subcohort of 10 episodes of S. aureus persistent bacteraemia treated with daptomycin at 4 -6 mg/kg, subsequent isolates from 6 (60%) episodes showed increased daptomycin MIC. 8 To our knowledge, our study is the first that includes a high proportion of patients with persistent MRSA bacteraemia treated with highdose regimens. Importantly, the rate of emergence of resistance was apparently similar to that observed in the clinical trial cited above, in which daptomycin therapy was administered in low-dose regimens. 7 However, since we only included episodes with persistent bacteraemia for ≥7 days, we must stress the existence of selection bias with respect to this other study. Despite the limitations related to the low number of episodes included, the present study provides valuable data regarding the incidence of daptomycin susceptibility loss during persistent MRSA bacteraemia and suggests an association of this phenomenon with subsequent therapeutic failure. As a consequence, our results reinforce the recommendation of monitoring daptomycin susceptibility in subsequent isolates to assess the risk of final therapeutic failure. Research letters
